The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung ...
The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.
【プレスリリース】発表日:2024年05月31日ゾルベツキシマブ FDAが承認再申請を受理- 承認された場合、米国でファーストインクラスの抗CLDN18.2モノクローナル抗体となる可能性あり -アステラス製薬株式会社(本社 : ...
Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.
The FDA has granted accelerated approval to IMDELLTRA™ for treating extensive-stage small cell lung cancer following platinum ...
The Food and Drug Administration last week approved an innovative new treatment for patients with a form of lung cancer. It ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' blockbuster ...
Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...